An exploratory study to characterise changes in airway inflammation, symptoms, lung function and reliever use in adult asthma patients

Study identifier:D589BC00018

ClinicalTrials.gov identifier:NCT03924635

EudraCT identifier:2018-003467-64

CTIS identifier:N/A

Study Complete

Official Title

A 24-week Randomised Exploratory Open-Label Study Aiming To Characterise Changes In Airway Inflammation, Symptoms, Lung Function, And Reliever Use In Asthma Patients Using SABA (Salbutamol) Or Anti-Inflammatory Reliever (SYMBICORT®) As Rescue Medication In Addition To SYMBICORT As Daily Asthma Controller

Medical condition

Airway inflammation

Phase

Phase 4

Healthy volunteers

No

Study drug

SYMBICORT and salbutamol

Sex

All

Actual Enrollment

42

Study type

Interventional

Age

18 Years - 100 Years

Date

Study Start Date: 01 Aug 2019
Primary Completion Date: 16 Dec 2022
Study Completion Date: 16 Dec 2022

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria